The Discounted Cash Flow (DCF) valuation of Sigilon Therapeutics, Inc. (SGTX) is (548.49) USD. With the latest stock price at 22.47 USD, the upside of Sigilon Therapeutics, Inc. based on DCF is -2541.0%.
Based on the latest price of 22.47 USD and our DCF valuation, Sigilon Therapeutics, Inc. (SGTX) is a sell. selling SGTX stocks now will result in a potential gain of 2541.0%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 8.1% | 6.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (2,565.99) - (313.14) | (548.49) |
| Upside | -11519.6% - -1493.6% | -2541.0% |